SPONSOR:

Rep. Bolden & Rep. Dorsey Walker & Sen. Hoffner

Reps. Baumbach, Bush, Heffernan, K. Johnson, Lynn, Morrison, Parker Selby, K. Williams, Wilson-Anton; Sens. Huxtable, Wilson

HOUSE OF REPRESENTATIVES

152nd GENERAL ASSEMBLY

HOUSE BILL NO. 302

AN ACT TO AMEND TITLE 18 OF THE DELAWARE CODE RELATING TO PROSTATE CANCER SCREENING.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF DELAWARE:

Section 1. Amend Chapter 33, Title 18 of the Delaware Code by making deletions as shown by strike through and insertions as shown by underline as follows:

§ 3346A. Prostate cancer screening.

(a) For purposes of this section:

(1) “Prostate screening” means a blood test for prostate-specific antigens that detect prostate cancer.

(2) “High risk of prostate cancer” means:

a. African American men over the age of 40.

b. Men over the age of 40 with a family history of prostate cancer.

(b) All individual health insurance policies, contracts, or certificates that are delivered, issued for delivery, renewed, extended, or modified in this State after December 31, 2024, shall provide coverage for annual prostate screening for men over the age of 40 with a high risk of prostate cancer at no cost to a covered individual, including deductible payments and cost-sharing amounts charged once a deductible is met.

(c) Except as provided under subsection (b) of this section, nothing in this section prevents the operation of a policy provision required by this section as a deductible, coinsurance, allowable charge limitation, coordination of benefits, or a provision restricting coverage to services by a licensed, certified, or carrier-approved provider or facility.

(d)(1) This section does not apply to accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, disability income, or other limited benefit health insurance policies.

(2) The cost-sharing limitation under subsection (b) of this section does not apply to a catastrophic health plan to the extent this cost-sharing limitation would cause the plan to fail to be treated as a catastrophic plan under § 1302(e) of the Patient Protection and Affordable Care Act, 42 U.S.C. § 18022(e).

(3) a. The cost-sharing limitation under subsection (b) of this section does not apply to a high deductible health plan to the extent this cost-sharing limitation would cause the plan to fail to be treated as a high deductible health plan under § 223(c)(2) of the Internal Revenue Code.

b. If the cost-sharing limitation under subsection (b) of this section would result in an enrollee becoming ineligible for a health savings account under federal law, this cost-sharing limitation only applies to a qualified high deductible health plan after the enrollee’s deductible has been met.

Section 2. Amend § 3552, Title 18 of the Delaware Code by making deletions as shown by strike through and insertions as shown by underline as follows:

§ 3552. Cancer screening tests.

(b) All group and blanket health insurance policies which are delivered or issued for delivery in this State by any health insurer or health service corporation and which provide benefits for outpatient services shall provide to covered persons residing or having their principal place of employment in this State and being age 50 or above a benefit for an annual prostate cancer screening, commonly known as a prostatic specific antigen (PSA) test. test for the following individuals:

(1) Men over the age of 50.

(2) African American men over the age of 40.

(3) Men over the age of 40 with a family history of prostate cancer.

Such screening shall be deemed a covered service, notwithstanding policy exclusions or services which are part of or related to annual or routine examinations.

Section 3. This Act takes effect January 1 following its enactment into law.

SYNOPSIS

This Act requires all group, blanket, and individual health insurance policies to cover prostate screening for men at high risk for prostate cancer who are over the age of 40. Men at high risk for prostate cancer means African American men or those with a family history of prostate cancer.